Moving faster than planned, AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) Less than a year after emerging from stealth operations with $12.7 million and partnerships with pharmaceutical giants, Seattle-based biotech startup Accipiter Biosciences has added $10.5 million to its funding total. The new cash will let the company move faster on promising drug candidates.